Autolus Therapeutics (AUTL) Non-Current Assets (2017 - 2025)

Autolus Therapeutics (AUTL) has reported Non-Current Assets for 9 consecutive years, with $153.2 million the latest figure, recorded in Q4 2025.

• Quarterly Non-Current Assets rose 25.75% year-over-year to $153.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $577.8 million (up 36.49% YoY) and the FY2025 annual result came in at $153.2 million, up 25.75% from the prior year.
• Non-Current Assets rose to $153.2 million in Q4 2025 per AUTL's latest filing, from $147.4 million in the prior quarter.
• Over the last five years, Non-Current Assets for AUTL reached as high as $153.2 million in Q4 2025 and fell as low as $2.5 million in Q3 2021.
• A 5-year average of $82.7 million and a median of $95.3 million in 2023 frame the typical range for Non-Current Assets.
• Annual changes were most pronounced in 2021 — Non-Current Assets declined 13.08% — and 2022, when it surged 1950.92%.
• Year by year, Non-Current Assets stood at $58.6 million in 2021, then grew by 10.06% to $64.5 million in 2022, then soared by 55.15% to $100.1 million in 2023, then grew by 21.7% to $121.8 million in 2024, then rose by 25.75% to $153.2 million in 2025.
• According to Business Quant data, Non-Current Assets over the past three periods registered $153.2 million, $147.4 million, and $146.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.